Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Industry-partnered Collaborative Research - Other Partner

Université Laval

$70,000.00

Isolation of therapeutic fractions from intravenous immunoglobulins using the triple transgenic mouse model of Alzheimer's disease

EF 2009-10

Résumé
Immunoglobulins (or antibodies) are proteins found in blood or other body fluids that are produced by the immune system to identify and neutralize foreign particles, such as bacteria and viruses. Intravenous immunoglobulin (IVIg) therapy consists in injecting to a patient a mixture of immunoglobulins that have been extracted from plasma pools of thousands of blood donors. This approach is successfully used to treat immunodeficient patients that do not produce enough immunoglobulins by their own blood cells. These patients completely rely on IVIg therapy to live. An increasing number of autoimmune or inflammatory diseases are also treated with IVIg. Recent evidence suggests that Alzheimer's disease (AD) patients may benefit from IVIg. However, the total pool of immunoglobulin available for this use is very limited. Thus, we need to better understand how IVIg therapy works if we want to be able to offer it to AD patients on a large scale. In the present grant application, we propose to identify the small fraction(s) of IVIg preparations displaying full efficiency and to study its mechanism of action. In summary, our research project aims to demonstrate the efficacy of IVIg therapy in an animal model and to shed light on the underlying mechanisms necessary for its clinical application in AD.
Programme
Operating Grant: Industry-partnered Collaborative Research - Other Partner
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
188970
Name
Calon Frédéric
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Hema-Quebec (Québec)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Isolation of therapeutic fractions from intravenous immunoglobulins using the triple transgenic mouse model of Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research - Other Partner
Keyworddelim
3xtg-Ad; Abeta; Alzheimer; Intravenous Immunoglobulin; Tau
Abstract
Immunoglobulins (or antibodies) are proteins found in blood or other body fluids that are produced by the immune system to identify and neutralize foreign particles, such as bacteria and viruses. Intravenous immunoglobulin (IVIg) therapy consists in injecting to a patient a mixture of immunoglobulins that have been extracted from plasma pools of thousands of blood donors. This approach is successfully used to treat immunodeficient patients that do not produce enough immunoglobulins by their own blood cells. These patients completely rely on IVIg therapy to live. An increasing number of autoimmune or inflammatory diseases are also treated with IVIg. Recent evidence suggests that Alzheimer's disease (AD) patients may benefit from IVIg. However, the total pool of immunoglobulin available for this use is very limited. Thus, we need to better understand how IVIg therapy works if we want to be able to offer it to AD patients on a large scale. In the present grant application, we propose to identify the small fraction(s) of IVIg preparations displaying full efficiency and to study its mechanism of action. In summary, our research project aims to demonstrate the efficacy of IVIg therapy in an animal model and to shed light on the underlying mechanisms necessary for its clinical application in AD.
Competitiondate
200909
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Calon, Frédéric
Approvedterm
4 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $70,000~ $0~